Literature DB >> 21984890

Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer.

Ian H Frazer1, Myron J Levin.   

Abstract

We compare the design, mechanism of action, and clinical efficacy of two recently licensed paradigm shifting vaccines. Zostavax is the first vaccine licensed to prevent disease in patients already infected with a pathogen, and is contrasted with Gardasil and Cervarix, the first vaccines designed and licensed specifically to prevent cancers.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21984890      PMCID： PMC3185382          DOI： 10.1016/j.coviro.2011.07.007

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN： 1879-6257            Impact factor:   7.090


  70 in total

1.  Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection.

Authors:  J J Carter; L A Koutsky; J P Hughes; S K Lee; J Kuypers; N Kiviat; D A Galloway
Journal:  J Infect Dis       Date:  2000-05-31       Impact factor: 5.226

2.  Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses.

Authors:  Adriana Weinberg; Ann A Lazar; Gary O Zerbe; Anthony R Hayward; Ivan S F Chan; Rupert Vessey; Jeffrey L Silber; Rob R MacGregor; Kenny Chan; Anne A Gershon; Myron J Levin
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

3.  A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers.

Authors:  T G Evans; W Bonnez; R C Rose; S Koenig; L Demeter; J A Suzich; D O'Brien; M Campbell; W I White; J Balsley; R C Reichman
Journal:  J Infect Dis       Date:  2001-04-24       Impact factor: 5.226

4.  Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types.

Authors:  Ting Zhang; Yufei Xu; Liang Qiao; Youchun Wang; Xueling Wu; Dongsheng Fan; Qinglin Peng; Xuemei Xu
Journal:  Vaccine       Date:  2010-03-06       Impact factor: 3.641

5.  Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.

Authors:  R B Roden; W H Yutzy; R Fallon; S Inglis; D R Lowy; J T Schiller
Journal:  Virology       Date:  2000-05-10       Impact factor: 3.616

Review 6.  Prevention and treatment of papillomavirus-related cancers through immunization.

Authors:  Ian H Frazer; Graham R Leggatt; Stephen R Mattarollo
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

7.  Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16.

Authors:  X S Chen; R L Garcea; I Goldberg; G Casini; S C Harrison
Journal:  Mol Cell       Date:  2000-03       Impact factor: 17.970

8.  Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites.

Authors:  J J Carter; M M Madeleine; K Shera; S M Schwartz; K L Cushing-Haugen; G C Wipf; P Porter; J R Daling; J K McDougall; D A Galloway
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

9.  Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Authors:  Nubia Muñoz; Susanne K Kjaer; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Eng Hseon Tay; Patricía J Garcia; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Marc Steben; F Xavier Bosch; Joakim Dillner; Warner K Huh; Elmar A Joura; Robert J Kurman; Slawomir Majewski; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine T Bryan; Lisa C Lupinacci; Katherine E D Giacoletti; Heather L Sings; Margaret K James; Teresa M Hesley; Eliav Barr; Richard M Haupt
Journal:  J Natl Cancer Inst       Date:  2010-02-05       Impact factor: 13.506

10.  An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age.

Authors:  Timo Vesikari; Pierre Van Damme; Niklas Lindblad; Ulrich Pfletschinger; David Radley; Desmond Ryan; Scott Vuocolo; Richard M Haupt; Dalya Guris
Journal:  Pediatr Infect Dis J       Date:  2010-04       Impact factor: 2.129
View more
  7 in total

1.  Adjuvants for Leishmania vaccines: from models to clinical application.

Authors:  Vanitha S Raman; Malcolm S Duthie; Christopher B Fox; Greg Matlashewski; Steven G Reed
Journal:  Front Immunol       Date:  2012-06-11       Impact factor: 7.561

2.  Use of Phage Display technology in development of canine visceral leishmaniasis vaccine using synthetic peptide trapped in sphingomyelin/cholesterol liposomes.

Authors:  Christina Monerat Toledo-Machado; Lilian Lacerda Bueno; Daniel Menezes-Souza; Ricardo Andrez Machado-de-Avila; Christophe Nguyen; Claude Granier; Daniella Castanheira Bartholomeu; Carlos Chávez-Olórtegui; Ricardo Toshio Fujiwara
Journal:  Parasit Vectors       Date:  2015-02-28       Impact factor: 3.876

3.  Blocking IL-10 signalling at the time of immunization does not increase unwanted side effects in mice.

Authors:  Guoying Ni; Zaowen Liao; Shu Chen; Tianfang Wang; Jianwei Yuan; Xuan Pan; Kate Mounsey; Shelley Cavezza; Xiaosong Liu; Ming Q Wei
Journal:  BMC Immunol       Date:  2017-08-15       Impact factor: 3.615

Review 4.  Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific.

Authors:  Liang-Kung Chen; Hidenori Arai; Liang-Yu Chen; Ming-Yueh Chou; Samsuridjal Djauzi; Birong Dong; Taro Kojima; Ki Tae Kwon; Hoe Nam Leong; Edward M F Leung; Chih-Kuang Liang; Xiaohong Liu; Dilip Mathai; Jiun Yit Pan; Li-Ning Peng; Eduardo Rommel S Poblete; Philip J H Poi; Stewart Reid; Terapong Tantawichien; Chang Won Won
Journal:  BMC Infect Dis       Date:  2017-03-15       Impact factor: 3.090

5.  Characterization of Episomal Replication of Bovine Papillomavirus Type 1 DNA in Long-Term Virion-Infected Saccharomyces Cerevisiae Culture.

Authors:  Quanmei Tu; Weixu Feng; Zhuo Chen; Qijia Li; Yu Zhao; Jun Chen; Pengfei Jiang; Xiangyang Xue; Lifang Zhang; Kong-Nan Zhao
Journal:  Virol Sin       Date:  2021-08-30       Impact factor: 4.327

Review 6.  The Status and Prospects of Epstein-Barr Virus Prophylactic Vaccine Development.

Authors:  Cong Sun; Xin-Chun Chen; Yin-Feng Kang; Mu-Sheng Zeng
Journal:  Front Immunol       Date:  2021-06-08       Impact factor: 7.561

7.  Epithelium Expressing the E7 Oncoprotein of HPV16 Attracts Immune-Modulatory Dendritic Cells to the Skin and Suppresses Their Antigen-Processing Capacity.

Authors:  Janin Chandra; Yan Miao; Natasha Romoff; Ian H Frazer
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.